Yahoo Finance2d
ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story
After the market closed on 3/24/25, Adaptimmune (NASDAQ:ADAP) filed the company’s Form 10-K Annual Report. ADAP reported a net loss of $74.2 million for 4Q24, or $(0.05) per diluted ordinary ...
Yahoo Finance7d
ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options
Pre-market open on 3/20/25, Adaptimmune (NASDAQ:ADAP) provided a business update for 4Q24 (in lieu of financial results for the quarter/full year to be released in conjunction with the company’s ...
Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.com
StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Thursday. The firm issued a buy rating on the biotechnology company’s ...